AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD

  • Hijiya, Nobuko (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date4/2/13 → 8/8/13

Funding

  • Children’s Hospital of Philadelphia (COG AAML1031)
  • Bayer HealthCare Pharmaceuticals, Inc. (COG AAML1031)